Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

on in managing their cholesterol levels.

"There is a lot of interest in PCSK9 as an exciting new target for the treatment of high cholesterol and having demonstrated that SPC5001 effectively lowers LDL or the 'bad' cholesterol in preclinical studies, we are quickly moving forward with plans to advance SPC5001 into clinical studies as a potential new treatment to help patients better manage the risks of cardiovascular diseases," said Henrik Orum, PhD, Vice President and Chief Scientific Officer of Santaris Pharma A/S. "SPC5001 is a testament to the efficiency of our LNA Drug Platform and Drug Discovery Engine as we discovered, optimized and advanced SPC5001 into preclinical development in just 18 months."

The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combines the Company's proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates for a range of diseases including metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.

"In addition to advancing SPC5001 into drug development for the treatment of high cholesterol, we remain on track to begin Phase 2 clinical trials of miravirsen (SPC3649) in patients with Hepatitis C in the second half of this year," said Soren Tulstrup, President and Chief Executive Officer, Santaris Pharma A/S. "In our internal programs and partnered programs, the versatility and broad utility of Santaris Pharma A/S LNA Drug Platform and Drug Discovery Engine continues to be critical in developing effective RNA-targeted therapies with high affinity, target specificity and remarkable potency for a range of diseases."

SPC5001 adds to the portfolio of Santaris Pharma A/S drugs in development, including its most advanced c
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 The California Healthcare ... organization representing leading California academic institutions, biotechnology, medical ... US today released a report revealing that ... growth. The trend shows a 4 percent increase ... Biomedical Industry Report indicates that, while biopharmaceutical ...
(Date:11/21/2014)... November 21, 2014 2014 Deep ... Industry” is a professional and in-depth research report ... ferrocyanide information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... nine month periods ended September 30, 2014.  Biorem,s complete 2014 third ... www.sedar.com ). Financial Summary:Three-months ended September 30, ... per share data) , 2014 , 2013 ... 2,282 , 5,281 , 6,715 , ...
(Date:11/18/2014)... November 17, 2014 Athena Signature Series: Turning ... Dr. Beverly Emerson, a professor in the Regulatory Biology Laboratory ... most recent discovery points to an “off switch” for drug ... and how her local research is making a global impact ... findings and then join host Cheryl K. Goodman, CEO of ...
Breaking Biology Technology:California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... The Foundation for,Biomedical Research (FBR) congratulates Congress for ... highest civilian honor it can bestow, the,Congressional Gold ... medicine,have improved the health of millions of American ... as a surgeon, inventor, educator and,medical statesman make ...
... Third Genmab Antibody,Summary: Genmab,s Partner Roche has Filed a CTA With ... ... Antibody, COPENHAGEN, October 2 Genmab A/S (OMX: GEN),announced today ... the British Medicines and Healthcare products,Regulatory Agency (MHRA) for a Genmab ...
... Presentation To Be Webcast -, MONTVALE, N.J., Oct. ... today that Noah Berkowitz, M.D., Ph.D.,President and Chief Executive ... October 11, 2007 at 11:00 a.m. PT. BIO InvestorForum ... the Palace Hotel in San Francisco, CA. Dr. ...
Cached Biology Technology:Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal 2Genmab A/S - Company Announcement 2Synvista Therapeutics to Present at the BIO InvestorForum 2007 2Synvista Therapeutics to Present at the BIO InvestorForum 2007 3
(Date:11/18/2014)... Nov. 17, 2014   News ... collaborate to develop The Partners Data Lake, an ... Partners Data Lake will allow researcher and clinicians ... treatment and the lives of patients , ... clinical activities across the Partners system, breaking down ...
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... the waters off the North Carolina coast, historically-significant World ... a testament to a relatively unknown chapter in U.S. ... are not only important for their cultural value, but ... invertebrates and algal species. Additionally, due to their unique ...
... 24, 2011 A team of scientists from The ... to kill the deadliest antibiotic-resistant bacteria. The compound could ... life-threatening and highly resistant bacterial infections. The results ... Journal of the American Chemical Society . ...
... AURORA, Colo. (Aug. 24, 2011) A scientist investigating ... motor coordination has found that key eye reflexes are substantially ... Medicine researcher Alberto Costa, MD, Ph.D., could lead to new ... aimed at improving quality of life for those with this ...
Cached Biology News:Scientists reengineer antibiotic to overcome dangerous antibiotic-resistant bacteria 2Scientists reengineer antibiotic to overcome dangerous antibiotic-resistant bacteria 3Scientists reengineer antibiotic to overcome dangerous antibiotic-resistant bacteria 4Researcher finds altered cerebella in those with Down syndrome 2
Request Info...
...
...
... agent. Inhibits several important steps of angiogenesis including ... cells. Also reduces intracellular reactive oxygen species (ROS) ... endothelial cells. Formula: ... MolWeight: 360.31484 ...
Biology Products: